Skip to content

Inflammation in Children With Attention-Deficit/Hyperactivity Disorder

Inflammation in Children With Attention-Deficit/Hyperactivity Disorder

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00391495
Acronym
ADHD_CYTO
Enrollment
45
Registered
2006-10-24
Start date
2007-09-30
Completion date
2007-12-31
Last updated
2007-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder

Keywords

ADHD, Cytokines, CR-P

Brief summary

The aim of this study is to investigate the inflammatory response in children with this disorder.

Detailed description

Attention deficit-hyperactivity disorder (ADHD) is a prevalent childhood neuropsychiatric disorder, characterized by age-inappropriate and impairing levels of inattention, hyperactivity and impulsiveness. Approximately 5-10% of school-age children are affected by ADHD, and in many cases, symptoms persist into adolescence and adulthood. Cytokines are key mediators of immune function and can be either pro-inflammatory or anti-inflammatory. Recently few studies have suggested involvement of cytokine pathways in subjects with ADHD. Polymorphism of IL-1 receptors antagonists' alleles have been suggested in families and subjects suffering from ADHD. Moreover, a new variant of inflammatory bowel disease, another immunological based disease, was recently suggested in children with ADHD and other developmental disorders. There are no other published reports on cytokine production in children who suffer from ADHD.

Interventions

PROCEDUREBlood drawing

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
9 Years to 13 Years
Healthy volunteers
Yes

Inclusion criteria

1. A defined condition of ADHD according to TOVA test (TOVA score \> (-1.8), Connor's questionnaire (Connor's score \> 15 points) and Achenbach's questionnaire; 2. A consent form signed by parents or legal guardianships;

Exclusion criteria

1. A history of any other neurological or major psychiatric disorder or other significant medical problems; 2. No current medications;

Countries

Israel

Contacts

Primary ContactNachum Vaisman, Prof. (MD)
vaisman@tasmc.health.gov.il972-3-6974807

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026